Daiichi Sankyo completes trio of major edoxaban filings
This article was originally published in Scrip
Executive Summary
Following a submission for the novel anticoagulant in the EU earlier this week, and in Japan in December, Daiichi Sankyo has filed an NDA for the US approval of edoxaban in what will be its main commercial indications.